Advertisement
U.S. markets open in 8 hours
  • S&P Futures

    5,208.75
    -6.00 (-0.12%)
     
  • Dow Futures

    39,211.00
    -12.00 (-0.03%)
     
  • Nasdaq Futures

    18,184.00
    -47.50 (-0.26%)
     
  • Russell 2000 Futures

    2,047.40
    -2.40 (-0.12%)
     
  • Crude Oil

    82.58
    -0.14 (-0.17%)
     
  • Gold

    2,162.20
    -2.10 (-0.10%)
     
  • Silver

    25.27
    +0.01 (+0.04%)
     
  • EUR/USD

    1.0870
    -0.0007 (-0.07%)
     
  • 10-Yr Bond

    4.3400
    0.0000 (0.00%)
     
  • Vix

    14.33
    -0.08 (-0.56%)
     
  • GBP/USD

    1.2714
    -0.0014 (-0.11%)
     
  • USD/JPY

    150.3270
    +1.2290 (+0.82%)
     
  • Bitcoin USD

    64,956.62
    -3,808.84 (-5.54%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,722.55
    -4.87 (-0.06%)
     
  • Nikkei 225

    39,942.73
    +202.33 (+0.51%)
     

3 picks for bent but not broken biotech

Given up for dead just weeks ago the biotech sector is suddenly back with a vengeance. Seemingly everyone’s favorite momentum darlings, or at the very least a group to rival social media for those who aren’t afraid of science, the iShares Biotechnology ETF (IBB) suffered a mini-bear market from February to April but never decisively collapsed.

With the ETF bouncing and the sector as a whole seemingly making a recovery, the billion dollar question for traders is whether this is a chance to make a graceful exit from long positions or the beginning of a whole new bull market for biotechs.

In the attached clip Oppenheimer’s Ari Wald says the sector has held its uptrend. “There are three things I like about (the sector): It’s oversold. It’s stabilizing on support and it’s still in an uptrend.”

From a technical perspective that makes the trade relatively simple. The stocks can be bought where they are with a stop loss set at or below prior support levels. On the IBB in particular Wald notes that the decline held the 200-day moving average. As you can see in the chart below the 200-day for the IBB is currently about $223. As long as it remains above that mark Wald will consider the upward trend to be in place.

Wald has three favorites within the group:

Biogen Idec (BIIB):

Alexion Pharmaceuticals (ALXN):

United Therapeutics (UTHR):

More from Breakout:

Stocks at all-time highs means take profits now: Kilburg

Market divergence: Dow hits new highs, but small caps still struggling

There’s still mojo in select tech stocks: Kilburg

Advertisement